anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
This is a Phase 1, randomized, double-blind, placebo-controlled, single-center, single escalating dose study in healthy Chinese subjects. The primary objective of the study is to characterize the pharmacokinetics (PK) of certolizumab pegol (CZP) in healthy Chinese subjects after a single subcutaneous (sc) dose. The secondary objective is to evaluate safety of CZP in healthy Chinese subjects after a single sc dose. 36 healthy Chinese subjects (18 male and 18 female) will be randomized to receive one of 3 dose levels of CZP (100 mg, 200 mg and 400 mg) or placebo given by sc injections. Each dose group begins treatment staggered by a minimum of 14 days. The total duration of the study will be approximately 71 to 94 days for each subject. This includes a 2 to 21 days Screening Period, 1 day of treatment and 70 days Observation Period after administration of a single dose of investigational medicinal product.
The present invention is based on an in vivo animal model that mimics human cellular and tissue degenerative disorders. The animal model exhibits cellular toxicity in response to expanded polyglutamine repeat sequences. The animal model is therefore useful for identifying genes or other compounds that modulate cellular and tissue degeneration and cell survival, for example, in neural, muscle, mesoderm, kidney and other tissues associated with frontotemporal dementia, prion diseases, polyglutamine disorders and protein aggregation disorders. Genes that suppress degeneration identified using the animal model include HDJ1, TPR2 and MLF. These genes, and their human homologues, functional fragments and probes are therefore useful in treating such disorders and for diagnostic purposes. Accordingly, methods for identifying nucleic acids and other compounds that modulate frontotemporal dementia, prion diseases, polyglutamine disorders and protein aggregation disorders is therefore provided. Pharmaceutical compositions comprising HDJ1, TPR2 and MLF genes, and subsequences encoding functional polypeptides are also provided, as they are useful in treating such degenerative disorders.
Participants randomized to the Standard Behavioral Weight Control (SBWC) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. The intervention includes a dietary plan, a fitness plan, behavioral weight control management that includes self-monitoring, goal-setting, stimulus control strategies, and planning, as well as parental involvement.
BACKGROUND: This study aimed to assess the quality and readability of large language model-generated responses to frequently asked questions (FAQs) about Kienböck's disease (KD).
METHODS: Nineteen FAQs about KD were selected, and the questions were divided into three categories: general knowledge, diagnosis, and treatment. The questions were inputted into the Chat Generative Pre-trained Transformer 4 (ChatGPT4) webpage using the zero-shot prompting method, and the responses were recorded. Hand surgeons with at least 5 years of experience and advanced English proficiency were individually contacted over instant WhatsApp messaging and requested to assess the responses. The quality of each response was analyzed by 33 experienced hand surgeons using the Global Quality Scale (GQS). The readability was assessed with the Flesch-Kincaid Grade Level (FKGL) and Flesch Reading Ease Score (FRES).
RESULTS: The mean GQS score was 4.28 out of a maximum of 5 points. Most raters assessed the quality as good (270 of 627 responses; 43.1%) or excellent (260 of 627 responses; 41.5%). The mean FKGL was 15.5, and the mean FRES was 23.4, both of which are considered above the college graduate level. No statistically significant differences were found in the quality and readability of responses provided for questions related to general knowledge, diagnosis, and treatment.
CONCLUSIONS: ChatGPT-4 provided high-quality responses to FAQs about KD. However, the primary drawback was the poor readability of these responses. By improving the readability of ChatGPT's output, we can transform it into a valuable information resource for individuals with KD.
LEVEL OF EVIDENCE: Level IV, Observational study.
Renal fibrosis is the major pathological changes of Chronic kidney disease (CKD). Piezo1, a mechanical sensitive ion channel, is implicated in organ fibrosis. However, the precise role of Piezo1 in CKD fibrosis is unknown. The aims of this study were to identify that the role of Piezo1 in CKD fibrosis and its potential involvement of mitochondrial dysfunction. We performed the study with the Piezo1 agonist Yoda1, Bax inhibitor BAI1, Piezo1 inhibitor GsMTx4 and detected the injury, fibrosis, apoptosis markers and mitochondrial dysfunction. The results showed that the levels of apoptosis, mitochondrial dysfunction, injury and fibrosis increased in TCMK-1 cells after treatment with Yoda1. However, these changes that induced by Yoda1 were relieved by BAI1. Similarly, inhibition Piezo1 with GsMTx4 also partly relieved the renal injury, renal fibrosis, apoptosis and mitochondrial dysfunction in vivo and vitro. In conclusion, we found Piezo1 promoted the initiation and development of renal fibrosis and inhibiting Piezo1 improved the fibrosis.
BACKGROUND: The diagnosis and management of fever of unknown origin pose significant challenges in the field of infectious diseases, as it is influenced by various factors. Infectious diseases have long been recognized as the primary etiology of fever of unknown origin. However, not all infectious diseases can definitively identify the causative pathogen and infection sites.
CASE PRESENTATION: we present a case report of an individual with fever, nausea, and anorexia but did not report any abdominal pain. Physical examination revealed no signs of abdominal tenderness. Repeated imaging studies including enhanced CT and color US of the appendix, only one color US suggested the possibility of appendicitis. Despite effective anti-infective treatment, the patient continued to experience low-grade fever, leading to the decision for laparoscopic exploration and subsequent appendectomy. Pathological findings confirmed the presence of appendicitis. After the surgical procedure, the patient's temperature and infectious markers returned to within normal range, ultimately leading to a diagnosis of appendicitis.
CONCLUSIONS: The atypical symptoms and signs, along with the negative imaging results, contribute to the under diagnosis of appendicitis and the progression of fever of unknown origin, thereby exacerbating the physical, mental, and economic burden on patients. Consequently, there are valuable insights to be gained regarding the management of both appendicitis and fever of unknown origin.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if precipitated or discolored.

Sotradecol (sodium tetradecyl sulfate injection) is for intravenous use only. The strength of solution required depends on the size and degree of varicosity. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. The dosage should be kept small, using 0.5 mL to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL.
BACKGROUND: Ischemic stroke still ranks as the most fatal disease worldwide. Blood-brain barrier (BBB) is a promising therapeutic target for protection. Brain microvascular endothelial cell is a core component of BBB, the barrier function maintenance of which can ameliorate ischemic injury and improve neurological deficit. Se-methyl L-selenocysteine (SeMC) has been shown to exert cardiovascular protection. However, the protection of SeMC against ischemic stroke remains to be elucidated. This research was designed to explore the protection of SeMC from the perspective of BBB protection.
METHODS: To simulate cerebral ischemic injury, C57BL/6J mice were subjected to middle cerebral artery occlusion/reperfusion (MCAO/R), and bEnd.3 was exposed to oxygen-glucose deprivation/reoxygenation (OGD/R). After the intervention of SeMC, the barrier function and the expression of tight junction and ferroptosis-associated proteins were determined. For mechanism exploration, LY294002 (Akt inhibitor) was introduced both in vivo and in vitro.
RESULTS: SeMC lessened the brain infarct volume and attenuated the leakage of BBB in mice. In vitro, SeMC improved cell viability and maintained the barrier function of bEnd.3 cells. The protection of SeMC was accompanied with ferroptosis inhibition and tight junction protein upregulation. Mechanism studies revealed that the effect of SeMC was reversed by LY294002, indicating that the protection of SeMC against ischemic stroke was mediated by the Akt signal pathway.
CONCLUSION: These results suggested that SeMC exerted protection against ischemic stroke, which might be attributed to activating the Akt/GSK3β signaling pathway and increasing the nuclear translocation of Nrf2 and β-catenin, subsequently maintaining the integrity of BBB.
PURPOSE: An oral hygiene composition containing an Eugenia caryophyllata Thunb. extract or a mixture thereof as an effective ingredient is provided which eliminates bad breath and has an excellent prophylactic and treating effect on periodontal gum disease while providing freshness. CONSTITUTION: Flowers of Eugenia caryophyllata Thunb. are dried, ground, extracted with water or an organic solvent, followed by filtering or centrifugal separation to remove impurities. The oral hygiene composition contains 0.05 to 5% by weight of the Eugenia caryophyllata Thunb. extract. For example, 1% by weight of the Eugenia caryophyllata Thunb. extract is mixed with 0.02% by weight of sodium fluoride, 12% by weight of ethanol, 0.5% by weight of sodium saccharide, 8% by weight of glycerin, 30% by weight of polydimethylsiloxane, 0.04% by weight of an emulsion and a suitable amount of a mandarin skin extract.
Purpose of the present research project is to study a new in-vivo test for abnormal platelet function and to study the effect of certain drugs on clinical bleeding. This is a randomized clinical trial of a new in-vivo test of platelet function known as the bleeding volume (BV) test which relies on an on-line measurement system. This trial will assess the sensitivity and specificity of the new BV test by studying the effects of aspirin which is known to affect platelet function in-vivo. This is not a clinical trial of drugs. This is a clinical trial of a novel laboratory test. The BV test results will be compared to the results of two commercially available platelet function tests (the VerifyNow test and the PFA-100 test) which requires 10 ml of blood taken from a peripheral vein.

The bleeding volume test is an extension of the classic Ivy Bleeding Time Test (BTT). The BTT, an in-vivo test for an abnormal bleeding tendency, involves making a small standardized cut in the skin and measuring the duration of bleeding. We hypothesize that measuring both the volume of blood lost (BV) and the BT will to provide a more useful test. The BV test is expected to provide an improved in-vivo technique for 1) investigating the effects of drugs on platelet function and 2) diagnosing diseases of abnormal platelet function such as von Willebrand disease (vWD), 3) identifying patients who are aspirin-resistant in the sense that they do not benefit from the beneficial effects of aspirin in preventing thromboembolic disease (heart attack and stroke), 4) providing insight into the effects of antithrombotic drugs such as clopidogrel, lidocaine and statins (HMG-CoA reductase inhibitors). The BV test will provide an inexpensive diagnostic test and improve patient care.
Obesity is associated with an increased risk for 13 different cancers. The increased risk for cancer in obesity is mediated by obesity-associated changes in the immune system. Obesity has distinct effects on different types of inflammation that are tied to tumorigenesis. For example, obesity promotes chronic inflammation in adipose tissue that is tumor-promoting in peripheral tissues. Conversely, obesity inhibits acute inflammation that rejects tumors. Obesity therefore promotes cancer by differentially regulating chronic versus acute inflammation. Given that obesity is chronic, the initial inflammation in adipose tissue will lead to systemic inflammation that could induce compensatory anti-inflammatory reactions in peripheral tissues to suppress chronic inflammation. The overall effect of obesity in peripheral tissues is therefore dependent on the duration and severity of obesity. Adipose tissue is a complex tissue that is composed of many cell types in addition to adipocytes. Further, adipose tissue cellularity is different at different anatomical sites throughout the body. Consequently, the sensitivity of adipose tissue to obesity is dependent on the anatomical location of the adipose depot. For example, obesity induces more inflammation in visceral than subcutaneous adipose tissue. Based on these studies, the mechanisms by which obesity promotes tumorigenesis are multifactorial and immune cell type-specific. The objective of our paper is to discuss the cellular mechanisms by which obesity promotes tumorigenesis by regulating distinct types of inflammation in adipose tissue and the tumor microenvironment.
The present invention is a system and method of Cannabinoid administration via inhalation of a nebulized Cannabinoid-Water. The system and method provide a variety of significant advantages over other methods of administering Cannabinoids. The system and method provide rapid effect onset, similar to most inhalation methods, as Cannabinoids are introduced directly to the bloodstream. The present invention provides a method of administering inhalable cannabinoids that virtually eliminates throat and lung irritation. The invented system produces a fine inhalable mist or vapor without any significant heating. Discomfort is largely eliminated, as are negative health effects related to inhalation of carcinogens related to smoke. The system is simple to operate and the method is easy to perform. The invention provides substantially improved dosing controllability versus other prevalent administration methods. The system and method tend to generate minimal local emissions, odors, or residues. [00044] The present invention is a system and method of Cannabinoid administration via inhalation of a nebulized Cannabinoid-Water. The system and method provide a variety of significant advantages over other methods of administering Cannabinoids. The system and method provide rapid effect onset, similar to most inhalation methods, as Cannabinoids are introduced directly to the bloodstream. The present invention provides a method of administering inhalable cannabinoids that virtually eliminates throat and lung irritation. The invented system produces a fine inhalable mist or vapor without any significant heating. Discomfort is largely eliminated, as are negative health effects related to inhalation of carcinogens related to smoke. The system is simple to operate and the method is easy to perform. The invention provides substantially improved dosing controllability versus other prevalent administration methods. The system and method tend to generate minimal local emissions, odors, or residues.
Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
A method for preparing multivalent proteosome-amphiphilic determinant vaccines suitable for parenteral or mucosal administration using diafiltration or ultrafiltration technology. The amphiphilic determinants include lipopolysaccharides from gram negative bacteria, e.g. S. flexneri, P.  shigelloides and S. sonnei. Proteosomes are obtained from group B type 2b meningococci. The active proteosome-amphiphilic determinant complexes (non-covalently complexes) of the vaccine are formed using diafiltration or ultrafiltration to remove the detergent. The use of diafiltration or ultrafiltration decreases processing time and the opportunity for contamination and further permits the use of ambient temperature and efficient scale-up. In addition, the process permits the reliable and continuous monitoring of the dialysate which enhances the efficiency of the entire process. The time of dialysis for production of a lot of vaccine is reduced from > 7-10 days to less than 72 hours and usually less than 48 or 24 hours.  The use of the process optimizes the presence of each antigenic component in the preparation of multivalent vaccines.
BACKGROUND AND OBJECTIVE: Surgical site infection (SSI) is common in surgery for malignant musculoskeletal tumours, specifically those arising from the trunk. In this study, we investigated the risk factors for SSI after resection of musculoskeletal tumours of the trunk.
METHODS: This retrospective observational study included 125 patients (72 males, 53 females) with musculoskeletal tumours of the trunk in our hospital from 1 April 2008 to 31 August 2023. The incidence of SSI and its risk factors were investigated.
RESULTS: SSI was observed in 26% (32/125), and the median time to SSI was 22 days. On multivariate analysis, the following were identified as risk factors for SSI: tumours arising caudal to Jacoby's line (hazard ratio [HR] 4.04; P = .0107), soft tissue reconstruction (HR 3.43; P = .0131), and low Geriatric Nutritional Risk Index (GNRI) (HR 0.96; P = .0304). Patients were classified into two risk categories based on GNRI scores: the risk group (GNRI ≤98) and no risk group (>98). The risk group showed a significantly lower overall noninfection survival rate (P = .023).
CONCLUSION: Tumours arising caudal to Jacoby line, soft tissue reconstruction, and lower GNRI were risk factors for SSI. Preoperative and postoperative nutritional interventions should be considered to improve GNRI.
The apparatus has a control unit (12,14) for controlling and monitoring a device and a display unit for displaying data. Intervention-specific data is accessible which encompasses data on the parameter values, which are set in the device during a predetermined intervention. The parameter values are predetermined partly independent of the user. The parameter values are called by a user for display by a display unit. The predetermined parameter values are taken for the device by actuating a confirmation element. Independent claims are also included for the following: (1) system for executing medical intervention (2) method for controlling and monitoring an apparatus during a medical intervention.
Osteosarcoma(OS) is a highly aggressive bone cancer for which treatment has remained essentially unchanged for decades. Although OS is characterized by extensive genomic heterogeneity and instability, RB1 and TP53 have been shown to be the most commonly inactivated tumor suppressors in OS. We previously generated a mouse model with a double knockout (DKO) of Rb1 and Trp53 within cells of the osteoblastic lineage, which largely recapitulates human OS with nearly complete penetrance. SKP2 is a repression target of pRb and serves as a substrate recruiting subunit of the SCFSKP2 complex. In addition, SKP2 plays a central role in regulating the cell cycle by ubiquitinating and promoting the degradation of p27. We previously reported the DKOAA transgenic model, which harbored a knock-in mutation in p27 that impaired its binding to SKP2. Here, we generated a novel p53-Rb1-SKP2 triple-knockout model (TKO) to examine SKP2 function and its potential as a therapeutic target in OS. First, we observed that OS tumorigenesis was significantly delayed in TKO mice and their overall survival was markedly improved. In addition, the loss of SKP2 also promoted an apoptotic microenvironment and reduced the stemness of DKO tumors. Furthermore, we found that small-molecule inhibitors of SKP2 exhibited anti-tumor activities in vivo and in OS organoids as well as synergistic effects when combined with a standard chemotherapeutic agent. Taken together, our results suggest that SKP2 inhibitors may reduce the stemness plasticity of OS and should be leveraged as next-generation adjuvants in this cancer.
The present invention relates to the field of biotechnology and medicine, and more particularly to oncology and pharmaceutics, and is directed toward finished dosage forms of a medicinal preparation for combined gene-directed enzyme prodrug therapy and immunotherapy of solid malignant tumours in humans. Proposed are two embodiments of two-component dosage forms of a medicinal preparation. In a first embodiment, the medicinal preparation comprises a first container and a second container, wherein the first container contains a first component containing therapeutic plasmid DNA of pCMV-HSVtk-hGM-CSF in a therapeutically effective amount in the form of a frozen aqueous solution, and the second container contains a second component containing a polyethylenimine – polyethylglycol – TAT peptide block copolymer in a therapeutically effective amount in the form of a frozen aqueous solution. A finished injection solution for administration to a patient is prepared ex tempore by thawing and mixing the two components. In a second embodiment, the medicinal preparation comprises a first container and a second container, wherein the first container contains a first component containing therapeutic plasmid DNA of pCMV-HSVtk-hGM-CSF in a therapeutically effective amount in the form of a lyophilizate, and the second container contains a second component containing a polyethylenimine – polyethylglycol – TAT peptide block copolymer in a therapeutically effective amount in the form of a frozen aqueous solution. A finished injection solution for administration to a patient is prepared ex tempore by reconstituting the first component by adding water, thawing the second component, and mixing the two components. The proposed medicinal preparations can be used to treat solid malignant tumours in humans. The two proposed dosage forms exhibit high stability and remain therapeutically effective for at least 18 months.
Monitor patients closely for hypersensitivity reactions, especially during the first and second infusions. Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. Severe hypersensitivity reactions require immediate discontinuation of the docetaxel infusion and aggressive therapy. Do not rechallenge patients with a history of severe hypersensitivity reactions with docetaxel injection [see Contraindications (4)]. 

Patients who have previously experienced a hypersensitivity reaction to paclitaxel may develop a hypersensitivity reaction to docetaxel that may include severe or fatal reactions such as anaphylaxis. Monitor patients with a previous history of hypersensitivity to paclitaxel closely during initiation of docetaxel injection therapy. Hypersensitivity reactions may occur within a few minutes following initiation of a docetaxel infusion. If minor reactions such as flushing or localized skin reactions occur, interruption of therapy is not required. All patients should be premedicated with an oral corticosteroid prior to the initiation of the infusion of docetaxel injection [see Dosage and Administration (2.6)].